Palisade Bio, Inc. (PALI)
NASDAQ:PALI
Want to see PALI full AI Analyst Report?
PALI Stock Chart & Stats
$2.40
-$0.36(-15.79%)
At close: 4:00 PM EST
$2.40
-$0.36(-15.79%)
Day’s Range― - ―
52-Week Range$0.53 - $2.86
Previous CloseN/A
Volume307.14K
Average Volume (3M)3.57M
Market Cap
$367.99M
Enterprise Value$235.36M
Total Cash (Recent Filing)$132.63M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.14
Next Earnings
Aug 25, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.06
Shares Outstanding173,579,670
10 Day Avg. Volume2,771,030
30 Day Avg. Volume3,568,241
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.01
Price to Sales (P/S)0.00
P/FCF Ratio-12.06
Enterprise Value/Market Cap0.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-8.86
Forecast
1Y Price Target
$10.67Price Target Upside344.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.22
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strategic Partnership & Equity InvestmentA formal collaboration plus a $3.0M equity infusion directly funds and accelerates PALI-2108 Phase 2 enrollment, shortening development timelines and lowering execution risk. This structural support improves trial throughput and alignment with a partner that can source patients over coming months.
Low Leverage Balance SheetNear-zero debt and a sizable equity base give the company financial flexibility to fund clinical programs, pursue partnerships, or absorb setbacks without heavy fixed-interest burdens. Low leverage supports strategic options and limits insolvency risk in a cash-burning R&D stage.
Reduced Cash-burn TrendAlthough free cash flow remains negative, the improvement versus the prior year signals management has slowed net cash outflows or benefited from timing/efficiency gains. A sustained reduction in burn rate lengthens runway and reduces near-term financing dependency.
Bears Say
No Commercial RevenueAs a clinical-stage biotech with no product sales, Palisade lacks a recurring revenue base and is dependent on successful trial outcomes or external funding to reach commercialization. This structural absence of revenue creates long lead-times to cash generation and valuation inflection.
Persistent Negative Cash FlowSustained negative operating and free cash flow requires repeated external financing or partner funding to sustain development. Continued cash burn increases dilution risk and constrains long-term planning unless offset by milestone payments, partnerships, or eventual revenue.
Widening Operating LossesGrowing operating losses reflect rising development and operating costs without offsetting revenue or clear operating leverage. Persistent widening losses erode equity returns (ROE ~ -48%) and amplify financing needs, raising execution risk through the clinical development cycle.
Palisade Bio News
PALI FAQ
What was Palisade Bio, Inc.’s price range in the past 12 months?
Palisade Bio, Inc. lowest stock price was $0.53 and its highest was $2.85 in the past 12 months.
What is Palisade Bio, Inc.’s market cap?
Palisade Bio, Inc.’s market cap is $367.99M.
When is Palisade Bio, Inc.’s upcoming earnings report date?
Palisade Bio, Inc.’s upcoming earnings report date is Aug 25, 2026 which is in 86 days.
How were Palisade Bio, Inc.’s earnings last quarter?
Palisade Bio, Inc. released its earnings results on May 12, 2026. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of -$0.043 by -$0.007.
Is Palisade Bio, Inc. overvalued?
According to Wall Street analysts Palisade Bio, Inc.’s price is currently Undervalued.
Does Palisade Bio, Inc. pay dividends?
Palisade Bio, Inc. does not currently pay dividends.
What is Palisade Bio, Inc.’s EPS estimate?
Palisade Bio, Inc.’s EPS estimate is -0.05.
How many shares outstanding does Palisade Bio, Inc. have?
Palisade Bio, Inc. has 173,579,670 shares outstanding.
What happened to Palisade Bio, Inc.’s price movement after its last earnings report?
Palisade Bio, Inc. reported an EPS of -$0.05 in its last earnings report, missing expectations of -$0.043. Following the earnings report the stock price went down -2.604%.
Which hedge fund is a major shareholder of Palisade Bio, Inc.?
Currently, no hedge funds are holding shares in PALI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Palisade Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.67 (344.44% Upside)
$10.67 (344.44% Upside)
Blogger Sentiment
Bullish
PALI Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.3%
Last 30 Days ▼ 6.5%
Last 30 Days ▼ 6.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
208.58%
12-Months-Change
Fundamentals
Return on Equity
-36.79%
Trailing 12-Months
Asset Growth
1527.78%
Trailing 12-Months
Company Description
Palisade Bio, Inc.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
PALI Stock 12 Month Forecast
Average Price Target
$10.67
▲(344.44% Upside)
Technical Analysis
Corbus Pharmaceuticals
―
Eledon Pharmaceuticals
―
―
Orchestra BioMed Holdings
―
Pyxis Oncology
―
Ownership Overview
0.03% Insiders
4.16% Mutual Funds
47.37% Other Institutional Investors
47.07% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---